Skip to content

Advertisement

  • Research article
  • Open Access

Involvement of Akt/CREB signaling pathways in the protective effect of EPA against interleukin-1β-induced cytotoxicity and BDNF down-regulation in cultured rat hippocampal neurons

BMC Neuroscience201819:52

https://doi.org/10.1186/s12868-018-0455-7

©  The Author(s) 2018

  • Received: 19 March 2018
  • Accepted: 31 August 2018
  • Published:

Abstract

Background

Our published data have indicated that the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) provides beneficial effects by attenuating neuronal damage induced by interleukin-1β (IL-1β), and up-regulation of the expression of brain-derived neurotrophic factor (BDNF) represents a crucial part in the neuroprotective effect of EPA. However, the mechanisms of how EPA regulates BDNF expression remains incompletely understood. The present study investigated the role of Akt/CREB signaling in the effect of EPA on BDNF expression and its neuroprotective effect.

Results

The present results showed that IL-1β reduced hippocampal neuronal viability and that EPA showed a concentration-dependent neuroprotective effect, but the neuroprotective effects of EPA were abolished by inhibition of Akt using KRX-0401, an inhibitor of Akt. Treatment of hippocampal neurons with EPA also ameliorated the decrease in Akt and CREB phosphorylation induced by IL-1β and BDNF down-regulation mediated by IL-1β. However, inhibition of Akt reversed the effect of EPA on levels of p-Akt, p-CREB, and BDNF.

Conclusions

Our data indicate that EPA elicited neuroprotection toward IL-1β-induced cell damage and BDNF decrease and that its effects potentially occurred via the Akt/CREB signaling pathway.

Keywords

  • Eicosapentaenoic acid
  • Brain-derived neurotrophic factor
  • Akt
  • Interleukin-1β

Background

Although the pathogenesis of neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), remains to be elucidated, neuroinflammation is considered one of the underlying factors of these disorders [1, 2]. Inflammation occurs in vulnerable brain regions of individuals with neurodegenerative disease, including the cortex, striatum and hippocampus, which is characterized by microglia activation and abnormally elevated levels of proinflammatory cytokines, such as interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-alpha (TNF-α) [3]. The excessive proinflammatory factors may cause persistent neuronal damage through different signaling pathways, including suppression of brain-derived neurotrophic factor (BDNF) [4]. BDNF is a critical neurotrophin associated with neuronal survival, differentiation and synaptic plasticity [5]. Accumulating studies have demonstrated the link between low BDNF levels and increased neuronal injury during a neurodegenerative disorder [6, 7]. Therefore, BDNF-augmenting treatments shall be beneficial to rescue neurons from neurodegenerative disease.

Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that cannot be synthesized by the human body. Our main sources of EPA are cold-water fish. There is increasing scientific evidence from epidemiology and animal studies linking EPA intake with brain health, which demonstrated parallel alterations between diets high in EPA and reduced risk of neurodegenerative disease [8–12]. Previously, we have reported that EPA markedly attenuated the IL-1β-induced BDNF decrease in the hippocampus, which may provide beneficial effects against inflammation-associated neurodegenerative changes [13]. However, the mechanisms underlying how EPA modulates BDNF still remain unclear.

Previous studies have shown that cAMP-response element binding protein (CREB) acts as a transcription factor and is present in many types of neurons [14–16]. Importantly, CREB-binding sequences have been identified in the BDNF gene [17]. CREB may be located upstream of BDNF and may up-regulate the expression of BDNF [18]. Before it works, some protein kinases, such as protein kinase A (PKA), Akt (also known as protein kinase B) or mitogen-activated protein kinase 2, are required to phosphorylate CREB at serine-133 and convert CREB to its active form [19]. Recently, since research has suggested that EPA can modify the activity of several protein kinases, including Akt [20], we therefore hypothesized that EPA would protect neurons by rescuing low levels of BDNF from IL-1β toxicity by regulating the Akt/CREB signaling pathways. In the present study, using the IL-1β-induced neuronal degeneration model, we investigated the protective role of EPA against cellular toxicity and examined the potential involvement of the Akt/CREB pathway in EPA-mediated neuroprotection and BDNF regulation.

Methods

Materials

IL-1β was purchased from R&D Systems (Minneapolis, MN, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT), DNAase1 and 1-β-D-arabinofuranosylcytosine were obtained from Sigma-Aldrich (Saint Louis, MO, USA). Neurobasal medium, B27 supplement, trypsin and TRIzol were purchased from Invitrogen Corporation (Carlsbad, CA, USA). The protease inhibitor mixture, phosphatase inhibitor, BCA protein assay kit and enhanced chemiluminescence substrate kit were obtained from Pierce Biotechnology (Rockford, IL, USA). RIPA lysis buffer was purchased from Beyotime Biotechnology (Shanghai, China). Akt (catalog No. 9272), phospho-Akt (catalog No. 5012S, Ser473), CREB (catalog No. 4820) and phospho-CREB (catalog No. 9198, Ser133) antibody were purchased from Cell Signaling Technology (Danvers, MA, USA). BDNF (catalog No. ab108319) and GAPDH (catalog No. ab37168) antibody were obtained from Abcam (Abcam, England). KRX-0401 (catalog No. S1037) was purchased from Selleck Chemicals LLC (Houston, TX, USA). An Ominiscript RT Kit and SYBR Green Kit were purchased from QIAGEN (Hilden, Germany). All other chemicals used were of the highest grade commercially available.

Cell culture

The primary hippocampal neurons were prepared as previously described with minor alterations [21]. Briefly, hippocampal tissues from Sprague–Dawley rats at embryonic day 18 were dissected in cold Ca2+ and Mg2+-free Hank’s balanced salt solution (HBSS), the tissues were mechanical dissociation using a Pasteur pipette after incubation with 0.25% trypsin and 50 µg/mL DNAase1 at 37 °C for 10 min. The cell suspensions were then transferred to a new tube, centrifuged at 1200 rpm for 3 min. The cell pellet was resuspended in serum-free neurobasal medium supplemented with 2% B27 supplement, 100 U/mL penicillin, and 100 µg/mL streptomycin, and then seeded on cell culture plates pre-coated with poly-l-lysine-coated. The cultures were grown in a humidified 5% CO2 atmosphere at 37 °C. 1-β-D-arabinofuranosylcytosine was added to the neuronal cultures on day in vitro 3 (DIV 3) to a final concentration of 2 µM to reduce glial cells proliferate. All treatments were performed on DIV 7. The animals obtained from Weitong Lihua Experimentary Animal Central (Beijing, China). Before to remove the fetuses, the pregnant rats were placed in a euthanasia chamber (40 × 18.5 × 25 cm, Rurui Science and Technology Instruments Co., Ltd, Guangzhou, China), and then filled with 100% CO2 at a delivered rate of 0.2 L/s from a compressed gas cylinder for 3 min. Heart, breath, pupil and pain were detected to make sure the animal’s death before dissection. All animal experimental procedures were approved by the Animal Care Committee of Yunnan University.

Experimental treatments

For the assessment of cell viability, cells were plated onto 96-well culture plates at 1 × 105 cells per well. For western blot and PCR assays, cells were plated onto 6-well culture plates at 1 × 106 cells per well. To investigate the toxicity effects of IL-1β, cells were treated at various times and with different concentrations of IL-1β, and cell viability was measured by MTT assay. To study the protective effects of EPA against IL-1β, the cells were pretreated with EPA for 40 min and then exposed to IL-1β for another 48 h. To determine whether or not the Akt/CREB signaling pathway was involved in the cell protection and BDNF regulation mediated by EPA, cells were pretreated with an Akt inhibitor (KRX-0401) for 30 min in conjunction with EPA and IL-1β. All experiments were performed using 3 separate cultures to confirm reproducibility.

MTT assay

Cell viability was assessed by the MTT assay at a designated time after the various treatments. MTT was added to the culture media at a final concentration of 0.5 mg/mL, after 4 h incubation at 37 °C, the supernatant was removed, and the MTT formazan crystals were dissolved with dimethyl sulfoxide (DMSO), the absorbance at 578 nm was read using a scanning multiwell plate reader (Tecan, Switzerland) after shaking the plates.

Western blot analysis

After the treatments, the cells were washed twice with cold phosphate-buffered saline (PBS) and harvested using cell scraper, and then lysed in RIPA buffer containing protease inhibitor mixture and phosphatase inhibitors on ice for 30 min. The protein concentrations were measured by BCA Protein Assay Kit. 30 µg of protein was separated by SDS polyacrylamide gel. Proteins were transferred to a PVDF membrane, incubated with fat-free milk for 2 h at room temperature for blocking nonspecific binding sites and further incubated overnight at 4 °C in fat-free milk containing the following primary antibodies: anti-Akt (1:1000), anti-phospho-Akt (1:1000), anti-CREB (1:2000), anti-phospho-CREB (1:1000), anti-BDNF (1:1000) and anti-GAPDH (1:5000). After washing, horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000) were applied to the membranes for 2 h at room temperature, immunostained bands were detected by enhanced chemiluminescence kit and quantified using Image-Pro Express 4.0 software (Media Cybernetics Inc. Rockville, MD, USA).

Real-time PCR

The total RNA will be extracted from cultured hippocampal neurons using TRIzol reagent, and the first stranded cDNA synthesized from 1 µg total RNA using the Ominiscript RT kit according to the manufacturer’s instructions. Polymerase chain reactions was performed by the Corbett Life Science Rotor-Gene (Sydney, Australia) 6000 system,the PCR reaction solution contained 7.5 µL SYBR Green Mix, 0.5 µL each primer (10 µM), 1 µL cDNA and 5.5 µL RNase-free water. Cycling parameters were set at an initial 15 min step at 95 °C, followed by 45 cycles of 94 °C for 15 s, 59 °C for 30 s and 72 °C for 30 s. All reactions were performed in triplicate. Gene expression levels were normalized to the expression of reference gene (beta actin) with the ΔΔCt method [13]. The specific primer pairs (Shanghai SangonBiotech, Shanghai, China) were as follows: BDNF: 5′-CAAAAGGCCAACTGAAGC-3′ (forward) and 5′-CGCCAGCCAATTCTCTTT-3′ (reverse); β-actin: 5′-GTCGTACCA CTGGCATTGTG-3′ (forward) and 5′-CTCTCAGCTGTGGTGGTGAA-3′ (reverse).

Statistical analysis

The data are presented as the mean ± SEM and statistical significance was evaluated by two-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test using SPSS 18.0 software, with P values less than 0.05 considered to be statistically significant.

Results

Cell viability in IL-1β-incubated hippocampal neurons

To determine the toxicity induced by IL-1β, we exposed the cultured hippocampal neurons to IL-1β (0.1–30 ng/mL) for 48 h, and the cell viability was assessed by the MTT assay. At the low IL-1β level (0.1 and 0.3 ng/mL), cell viability increased slightly, but there was no statistical difference compared to control cells (Fig. 1a). From 1 to 30 ng/mL, IL-1β induced cell damage in a dose-dependent manner, but only high concentration (20 and 30 ng/mL) IL-1β induced significant cell damage (both P < 0.01 compared to control cells), and the 30 ng/mL IL-1β elicited worse cell damage, which shown cell viability decreased sharply close to 60% of the control level. We then examined the time-dependent effect of IL-1β on cell damage. Figure 1b shows that cell viability was significantly decreased after hippocampal neurons were exposed to IL-1β for 24 h. Although cell viability showed more decline while the cells were exposed to IL-1β for 72 h, there was no significant difference compared to the cells exposed to IL-1β for 48 h. Based on this result, 20 ng/mL IL-1β and 48 h exposure time were selected for the subsequent experiments.
Fig. 1
Fig. 1

Cell viability was determined by MTT assay. a Cultured rat hippocampal neurons were treated with the indicated concentrations (0.1–30 ng/mL) of IL-1β for 48 h. b Cultured rat hippocampal neurons were treated with 20 ng/mL IL-1β for the indicated time. Percentage of cell viability was relative to the untreated control cells. *P < 0.05, **P < 0.01 versus control group (n = 6)

EPA reversed IL-1β-induced cell damage, but the protective effect was blocked by inhibiting Akt

We then investigated the effects of EPA on IL-1β-induced cell damage. The MTT assay showed that pretreatment with EPA enhanced cell viability in a concentration-dependent manner (Fig. 2a). The pro-survival effect of EPA was observed at 10 µM (P < 0.01 compared to IL-1β treated cells). We next investigated if Akt signaling is involved in EPA’s neuroprotective effect. Hippocampal neurons were pretreated with KRX-0401 (45 µM) to inhibit Akt [22] and then exposed to IL-1β in the presence or absence of EPA (10 µM). Figure 2b shows that IL-1β triggered a significant decrease in cell viability, whereas EPA significantly alleviated cytotoxicity mediated by IL-1β; however, the protective effect of EPA against IL-1β-induced cell damage was attenuated by KRX-0401, suggesting the involvement of the Akt pathways.
Fig. 2
Fig. 2

Protective effects of EPA on IL-1β triggered cell damage in cultured rat hippocampal neurons. Cell viability was determined by MTT assay. a Cells were pre-treated with the indicated concentrations (1–50 µM) of EPA for 40 min and then exposed to IL-1β (20 ng/mL) for another 48 h. b Cells were pretreated with KRX-0401 and EPA and then treated with IL-1β for 48 h. Percentage of cell viability was relative to the untreated control cells. **P < 0.01 versus control group; ##P < 0.01 versus IL-1β group

EPA rescued decline of Akt and CREB phosphorylation in IL-1β-treated hippocampal neurons, and this effect was blocked by Akt inhibitor

We assessed the role of the Akt/CREB pathway in the survival-promoting effect of EPA in hippocampal neurons. As shown in Fig. 3, IL-1β inhibited the phosphorylation of Akt and CREB in hippocampal neurons, which was consistent with the finding that IL-1β decreased cell viability. While the cells were cultured with EPA, the inhibitory effect of IL-1β on protein phosphorylation was reversed, which was also consistent with the results that the effect of EPA against cell damage was induced by IL-1β. However, when the cells were pretreated with KRX-0401 and then treated with EPA and IL-1β, the improvement of EPA on Akt and CREB phosphorylation and cell viability was blocked, confirming that the neuroprotective effect is mediated by the Akt/CREB pathway.
Fig. 3
Fig. 3

The effect of EPA on Akt and CREB phosphorylation was blocked by inhibition of the Akt signal, in the presence of IL-1β in cultured rat hippocampal neurons. a Cells pretreated with KRX-0401 and then treated with EPA and IL-1β, and the proteins expression was measured by western blotting. b Relative levels of proteins were determined by densitometry of the immunoblots. Data were normalized by taking the value of the control group as 1. **P < 0.01 versus control group; ##P < 0.01 versus IL-1β group

EPA regulated BDNF levels via the Akt/CREB pathway

As shown in Fig. 4, IL-1β significantly down-regulated BDNF expression at both the mRNA and protein levels. The down-regulation of BDNF expression induced by IL-1β was also significantly attenuated by EPA. However, application of KRX-0401 inhibited the effects of EPA on BDNF expression, suggesting that EPA regulated BDNF expression in an Akt/CREB-dependent manner.
Fig. 4
Fig. 4

EPA reversed the inhibitory effects of IL-1β on the expression of BDNF via the Akt/CREB pathways in cultured rat hippocampal neurons. a BDNF mRNA and protein, b expression were measured by real-time PCR and western blotting, respectively. c Relative levels of BDNF protein were determined by densitometry of the immunoblots. Data from PCR and western blotting were normalized by taking the value of the control group as 1. **P < 0.01 versus control group; ##P < 0.01 versus IL-1β group

Discussion

The present results showed that IL-1β caused neurotoxicity in hippocampal neurons, and EPA attenuated cell damage and BDNF down-regulation in correlation with Akt/CREB pathway activation. This notion is supported by the following observations: (1) Treatment with IL-1β in cultured hippocampal neurons caused cell damage, while EPA significantly reversed the toxic effect of IL-1β; (2) Akt and CREB phosphorylation was inhibited by IL-1β, while EPA prevented this inhibition; (3) inhibition of Akt/CREB blocked the neuroprotective effect of EPA toward IL-1β-induced cell damage; (4) the beneficial effect of EPA on BDNF expression was blocked by inhibiting Akt/CREB signaling. The present study confirms that EPA acts as a neuroprotector in the hippocampus and that this is accompanied by improving phosphorylation of Akt and CREB to augment BDNF expression.

IL-1β is a pluripotent proinflammatory cytokine that may activate a host’s defense system against infection and injury both in the peripheral immune system and in the central nervous system (CNS). Similar to Araujo and colleagues’ study, which reported that IL-1β is neurotoxic only at high concentrations and after relatively long exposure [23], in the present study, we found that low IL-1β (0.1 and 0.3 ng/mL) promoted cell growth slightly instead of exacerbating neuron damage. The beneficial effect of IL-1β on cell viability maybe due to IL-1β functioning as a paracrine growth factor to promote cell proliferation [24]. Indeed, our previous data reported that acute IL-1β administration can up-regulate nerve growth factor (NGF) expression, the increase in NGF levels could contribute to improving neuronal vitality [25]. Taking our findings together, we speculated that physiologically, even a slight increase in IL-1β levels benefit neuron health and regulate the expression of neurotrophic factors that play a role in this effect. In particular, the interrelations between low IL-1β and neurotrophic factor should also be investigated in the future.

Under abnormal conditions, such as in neurodegenerative disease, microglia can be over-activated in the CNS, and the over-activation of microglia can produce excessive proinflammatory cytokines, especially IL-1β [26]. Elevated IL-1β could cause a state of chronic inflammation and evoke multiple signaling, such as NF-κB and MAPK pathways, leading to cell damage [27–29]. Thus, we are not surprised to find that cell viability decreased significantly in the neurons that received high IL-1β in this study. More importantly, when the cells were preincubated with EPA, the cell viability was improved. This finding supports that EPA is highly neuroprotective against IL-1β. It should be pointed out that IL-1β can affect signal transduction associated with BDNF. For instance, it is has been reported that IL-1β suppressed Akt activation, the upstream signaling pathway involved in BDNF expression [30], it also demonstrated that IL-1β compromised phosphorylation of CREB, a transcription factor regulating BDNF expression [31], suggesting IL-1β places neurons at risk by interfering with BDNF signaling involving a Akt/CREB-associated mechanism. Our past work found EPA treatment restored BDNF decline induced by IL-1β administration rats provides a plausible explanation for the EPA’s neuroprotective effects maybe BDNF dependent [13]. Furthermore, the present findings showed that the protective effect of EPA against IL-1β-induced cell damage was attenuated by KRX-0401, it should be surmised that Akt/CREB may be a candidate to contribute the BDNF regulation mediated by EPA.

Akt is a member of the AGC (cAMP-dependent, cGMP-dependent and protein kinase C) kinase family. Activation of Akt via phosphorylation involved in multiple physiological and pathological effects response by phosphorylate a variety downstream molecules including of CREB [32–35]. Reportedly, the decrease in Akt and CREB phosphorylation was associated with neuron loss in neurodegenerative disease animal models, whereas enhanced Akt/CREB activity in the brain produced a beneficial effect on inhibiting neuroinflammation and improving neuronal function [36]. Under our experimental conditions, IL-1β decreased the phosphorylation of Akt and CREB. This is consistent with the finding of Soiampornkul et al. [37], who observed that the phosphorylation of Akt and CREB has been inhibited in cortical neurons that received IL-1β. Additionally, in our study, EPA antagonized the decline in Akt and CREB phosphorylation induced by IL-1β. However, in the presence of an Akt inhibitor, the EPA-mediated increase in Akt and CREB phosphorylation was partially blocked, as well as the EPA-dependent protective effect on neurons. Collectively, our data indicated that EPA may neutralize neurotoxicity mediated by IL-1β via Akt/CREB phosphorylation.

As stated above, BDNF is a direct target of CREB, and phosphorylated CREB binds to the cAMP response element (CRE) sequence 5′-TGACGTCA-3′ in the BDNF promoter region, this binding may promote the transcription activity of BDNF and increase its expression [38]. Consistent with the changes in CREB, we found that IL-1β suppresses CREB phosphorylation accompanied by a low BDNF expression, while EPA acted against these alterations. The deficiency of BDNF is believed to be a cause of neurodegeneration, and the up-regulation of BDNF may reduce neuroinflammation and hippocampal damage [39, 40]. Therefore, with the elevation of BDNF, the present results indicated EPA exposure restored cell viability that was inhibited by IL-1β; however, the application of an Akt inhibitor is sufficient to attenuate the positive effect of EPA on BDNF expression. Thus, it can be suggested that the regulation of BDNF by EPA under neuroinflammatory conditions is mediated by the Akt/CREB signaling pathway.

Conclusions

Our findings extend previous data on the role of EPA in neuronal protection and show that EPA promoted the expression of BDNF, probably via activation of the Akt/CREB pathway. These results confirmed that EPA might constitute a promising alternative for the prevention of neuroinflammation-associated neurodegenerative diseases.

Abbreviations

AD: 

Alzheimer’s disease Parkinson’s disease (PD)

AGC: 

cAMP-dependent, cGMP-dependent and protein kinase C

BDNF: 

brain-derived neurotrophic factor

CNS: 

central nervous system

CRE: 

cAMP response element

CREB: 

cAMP-response element binding protein

DMSO: 

dimethyl sulfoxide

EPA: 

eicosapentaenoic acid

IL-1β: 

interleukin-1β

MTT: 

methyl thiazolyl tetrazolium

NGF: 

nerve growth factor

PBS: 

phosphate-buffered saline

PD: 

Parkinson’s disease

PKA: 

protein kinase A

NF-α: 

tumor necrosis factor-alpha

Declarations

Authors’ contributions

This study is based on an original idea of YLD and YMW. YLD and YMW performed statistical analysis, drafted the manuscript, which was discussed and critically edited by all coauthors. KJP, WJD and HCC did the experiments including cell culture, MTT and western blot. KJP and LXC performed PCR assay. All authors read and approved the final manuscript.

Acknowledgements

Thanks are expressed to all co-investigators and laboratory technicians’ assistants.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All animal experiments were conducted under the guidelines for laboratory animals of the School of Medicine, Yunnan University. The animal research protocols were reviewed and approved by the Animal Care Committee of Yunnan University (permit number: YNU-17-012).

Funding

This work was supported by grants from the National Nature Science Foundation of China (Nos. 81360179; 81560197) and the Science and Technology project of Yunnan Provincial Science and Technology Department (2016FB132; 2015FB118). The funders do not participate in the experimental research, or preparation the manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
School of Medicine, Yunnan University, 2 Cuihu Bei Road, Kunming, 650091, Yunnan, People’s Republic of China
(2)
The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, 650031, Yunnan, People’s Republic of China

References

  1. Alam Q, Alam MZ, Mushtaq G, Damanhouri GA, Rasool M, Kamal MA, Haque A. Inflammatory process in Alzheimer’s and Parkinson’s diseases: central role of cytokines. Curr Pharm Des. 2016;22(5):541–8.View ArticlePubMedGoogle Scholar
  2. Bolós M, Perea JR, Avila J. Alzheimer’s disease as inflammatory disease. Biomol Concepts. 2017;8(1):37–43.View ArticlePubMedGoogle Scholar
  3. Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, Zahoor H, Zaheer S, Iyer SS, Zaheer A. Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine. 2016;1(1):1003.PubMedPubMed CentralGoogle Scholar
  4. Carlos AJ, Tong L, Prieto GA, Cotman CW. IL-1β impairs retrograde flow of BDNF signaling by attenuating endosome trafficking. J Neuroinflammation. 2017;14(1):29.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Benarroch EE. Brain-derived neurotrophic factor: regulation, effects, and potential clinical relevance. Neurology. 2015;84(16):1693–704.View ArticlePubMedGoogle Scholar
  6. Braun DJ, Kalinin S, Feinstein DL. Conditional depletion of hippocampal brain-derived neurotrophic factor exacerbates neuropathology in a mouse model of Alzheimer’s disease. ASN Neuro. 2017;9(2):1759091417696161.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Hernandez-Chan NG, Bannon MJ, Orozco-Barrios CE, Escobedo L, Zamudio S, De la Cruz F, et al. Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson’s disease. J Biomed Sci. 2015;22:59.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Hjorth E, Zhu M, Toro VC, Vedin I, Palmblad J, Cederholm T, et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimers Dis. 2013;35(4):697–713.View ArticlePubMedGoogle Scholar
  9. Luchtman DW, Meng Q, Song C. Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson’s disease. Behav Brain Res. 2012;226(2):386–96.View ArticlePubMedGoogle Scholar
  10. Robertsa RO, Cerhana JR, Geda YE, Knopman DS, Cha RH, Christianson TJ, et al. Polyunsaturated fatty acids and reduced odds of MCI: the mayo clinic study of aging. J Alzheimers Dis. 2010;21(3):853–65.View ArticleGoogle Scholar
  11. Solfrizzi V, D’Introno A, Colacicco AM, Capurso C, Del Parigi A, Capurso S, et al. Dietary fatty acids intake: possible role in cognitive decline and dementia. Exp Gerontol. 2005;40(4):257–70.View ArticlePubMedGoogle Scholar
  12. Solfrizzi V, Frisardi V, Capurso C, D’Introno A, Colacicco AM, Vendemiale G, et al. Dietary fatty acids in dementia and predementia syndromes: epidemiological evidence and possible underlying mechanisms. Ageing Res Rev. 2010;9(2):184–99.View ArticlePubMedGoogle Scholar
  13. Dong Y, Xu M, Kalueff AV, Song C. Dietary eicosapentaenoic acid normalizes hippocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates glial activation and regulates BDNF function in a rodent model of neuroinflammation induced by central interleukin-1β administration. Eur J Nutr. 2017;57:1751–91. https://doi.org/10.1007/s00394-017-1462-7.Google Scholar
  14. Landeira BS, Santana TT, Araújo JA, Tabet EI, Tannous BA, Schroeder T, et al. Activity-independent effects of CREB on neuronal survival and differentiation during mouse cerebral cortex development. Cereb Cortex. 2018;28(2):538–48.PubMedGoogle Scholar
  15. Gao HL, Xu H, Xin N, Zheng W, Chi ZH, Wang ZY. Disruption of the CaMKII/CREB signaling is associated with zinc deficiency-induced learning and memory impairments. Neurotox Res. 2011;19(4):584–91.View ArticlePubMedGoogle Scholar
  16. Stern CM, Luoma JI, Meitzen J, Mermelstein PG. Corticotropin releasing factor-induced CREB activation in striatal neurons occurs via a novel Gβγ signaling pathway. PLoS ONE. 2011;6(3):e18114.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Yossifoff M, Kisliouk T, Meiri N. Dynamic changes in DNA methylation during thermal control establishment affect CREB binding to the brain-derived neurotrophic factor promoter. Eur J Neurosci. 2008;28(11):2267–77.View ArticlePubMedGoogle Scholar
  18. Palomer E, Carretero J, Benvegnù S, Dotti CG, Martin MG. Neuronal activity controls Bdnf expression via Polycomb de-repression and CREB/CBP/JMJD3 activation in mature neurons. Nat Commun. 2016;7:11081.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Rosa E, Fahnestock M. CREB expression mediates amyloid β-induced basal BDNF downregulation. Neurobiol Aging. 2015;36(8):2406–13.View ArticlePubMedGoogle Scholar
  20. Marzuca-Nassr GN, Vitzel KF, De Sousa LG, Murata GM, Crisma AR, Junior CFR, et al. Effects of high EPA and high DHA fish oils on changes in signaling associated with protein metabolism induced by hindlimb suspension in rats. Physiol Rep. 2016;4(18):e12958.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Dong YL, Zuo PP, Li Q, Liu FH, Dai SL, Ge QS. Protective effects of phytoestrogen α-zearalanol on beta amyloid 25–35 induced oxidative damage in cultured rat hippocampal neurons. Endocrine. 2007;32(2):206–11.View ArticlePubMedGoogle Scholar
  22. Zeng B, Li Y, Niu B, Wang X, Cheng Y, Zhou Z, et al. Involvement of PI3 K/Akt/FoxO3a and PKA/CREB signaling pathways in the protective effect of fluoxetine against corticosterone-induced cytotoxicity in PC12 cells. J Mol Neurosci. 2016;59(4):567–78.View ArticlePubMedGoogle Scholar
  23. Araujo DM, Cotman CW. Differential effects of interleukin-1β and interleukin-2 on glia and hippocampal neurons in culture. Int J Dev Neurosci. 1995;13(3–4):201–12.View ArticlePubMedGoogle Scholar
  24. Lonnemann G, Shapiro L, Engler-Blum G, Muller GA, KochK M, Dinarello CA. Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int. 1995;47(3):837–44.View ArticlePubMedGoogle Scholar
  25. Song C, Zhang Y, Dong Y. Acute and subacute IL-1β administrations differentially modulate neuroimmune and neurotrophic systems: possible implications for neuroprotection and neurodegeneration. J Neuroinflammation. 2013;10:59.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Ramirez AI, de Hoz R, Salobrar-Garcia E, Salazar JJ, Rojas B, Ajoy D, et al. The role of microglia in retinal neurodegeneration: Alzheimer’s disease, Parkinson, and glaucoma. Front Aging Neurosci. 2017;9:214.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Swaroop S, Sengupta N, Suryawanshi AR, Adlakha YK, Basu A. HSP60 plays a regulatory role in IL-1β-induced microglial inflammation via TLR4-p38 MAPK axis. J Neuroinflammation. 2016;13:27.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Rossi S, Motta C, Studer V, Macchiarulo G, Volpe E, Barbieri F, et al. Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. Mol Neurodegener. 2014;9:56.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Ji B, Guo W, Ma H, Xu B, Ma W, Zhang Z, et al. Isoliquiritigenin suppresses IL-1β induced apoptosis and inflammation in chondrocyte-like ATDC5 cells by inhibiting NF-κB and exerts chondroprotective effects on a mouse model of anterior cruciate ligament transection. Int J Mol Med. 2017;40(6):1709–18.PubMedPubMed CentralGoogle Scholar
  30. Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW. Interleukin-1β impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging. 2008;29(9):1380–93.View ArticlePubMedGoogle Scholar
  31. Tong L, Prieto GA, Kramar EA, Smith ED, Cribbs DH, Lynch G, et al. Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase. J Neurosci. 2012;32(49):17714–24.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Hu M, Liu Z, Lv P, Wang H, Zhu Y, Qi Q, et al. Autophagy and Akt/CREB signalling play an important role in the neuroprotective effect of nimodipine in a rat model of vascular dementia. Behav Brain Res. 2017;325(3):79–86.View ArticlePubMedGoogle Scholar
  33. Zhang L, Zhao H, Zhang X, Chen L, Zhao X, Bai X, et al. Nobiletin protects against cerebral ischemia via activating the p-Akt, p-CREB, BDNF and Bcl-2 pathway and ameliorating BBB permeability in rat. Brain Res Bull. 2013;96:45–53.View ArticlePubMedGoogle Scholar
  34. Simão F, Matté A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3β and CREB through PI3-K/Akt pathways. Eur J Neurosci. 2012;36(7):2899–905.View ArticlePubMedGoogle Scholar
  35. Brazil DP, Hemmings BA. Ten years of protein kinase B signaling: a hard Akt to follow. Trends Biochem Sci. 2001;26(11):657–64.View ArticlePubMedGoogle Scholar
  36. Braidy N, Essa MM, Poljak A, Selvaraju S, AI-Adawi S, Manivasagm T, et al. Consumption of pomegranates improves synaptic function in a transgenic mice model of Alzheimer’s disease. Oncotarget. 2016;7(40):64589–604.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Soiampornkul R, Tong L, Thangnipon W, Balazs R, Cotman CW. Interleukin-1β interferes with signal transduction induced by neurotrophin-3 in corticalneurons. Brain Res. 2008;1188:189–97.View ArticlePubMedGoogle Scholar
  38. Suzuki A, Fukushima H, Mukawa T, Toyoda H, Wu LJ, Zhao MG, et al. Upregulation of CREB-mediated transcription enhances both short- and long-term memory. J Neurosci. 2011;31(24):8786–802.View ArticlePubMedGoogle Scholar
  39. Khallaf WAI, Messiha BAS, Abo-Youssef AMH, EI-Sayed NS. Protective effects of telmisartan and tempol on lipopolysaccharide-induced cognitive impairment, neuroinflammation, and amyloidogenesis: possible role of brain-derived neurotrophic factor. Can J Physiol Pharmacol. 2017;95(7):850–60.View ArticlePubMedGoogle Scholar
  40. Xu D, Lian D, Wu J, Liu Y, Zhu M, Sun J, et al. Brain-derived neurotrophic factor reduces inflammation and hippocampal apoptosis in experimental Streptococcus pneumoniae meningitis. J Neuroinflammation. 2017;14(1):156.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement

BMC Neuroscience

ISSN: 1471-2202

Contact us